Mechanisms of thrombosis in obesity

Current Opinion in Hematology

Volumn 20, Issue 5, 2013, Pages 437-444

  Blokhin, Ilya O ^a   Lentz, Steven R ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

fibrinolysis; inflammation; obesity; thrombosis

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; LEPTIN; MICRORNA; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PIOGLITAZONE; RESISTIN; SERINE PROTEINASE INHIBITOR;

CHRONIC INFLAMMATION; CYTOKINE RELEASE; FIBRINOLYSIS; HUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; THROMBOCYTE; THROMBOSIS;

ADIPOKINES; ADIPOSE TISSUE; ANTICOAGULANTS; FIBRINOLYSIS; HUMANS; OBESITY; PLATELET AGGREGATION INHIBITORS; THROMBOSIS;

EID: 84883279663     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e3283634443     Document Type: Review

References (97)

1. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics: 2013 update -a report from the American Heart Association. Circulation 2013; 127:e6-e245.
2. World Health Organization Fact Sheet N311In: Obesity and overweight; 2013.
3. Wolk R, Berger P, Lennon RJ, et al. Body mass index: a risk factor for unstable angina and myocardial infarction in patients with angiographically confirmed coronary artery disease. Circulation 2003; 108:2206-2211.
4. Yusuf S, Hawken S, Ounpuu S, et al. Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study. Lancet 2005; 366:1640-1649.
5. Rexrode KM, Hennekens CH, Willett WC, et al. A prospective study of body mass index, weight change, and risk of stroke in women. JAMA 1997; 277:1539-1545.
6. Suk SH, Sacco RL, Boden-Albala B, et al. Abdominal obesity and risk of ischemic stroke: the Northern Manhattan Stroke Study. Stroke 2003; 34: 1586-1592.
7. Stein PD, Beemath A, Olson RE. Obesity as a risk factor in venous thromboembolism. Am J Med 2005; 118:978-980.
8. Parkin L, Sweetland S, Balkwill A, et al. Body mass index, surgery, and risk of venous thromboembolism in middle-aged women: a cohort study. Circulation 2012; 125:1897-1904.
9. Tchernof A, Despres JP. Pathophysiology of human visceral obesity: an update. Physiol Rev 2013; 93:359-404.
10. Vandanmagsar B, Youm YH, Ravussin A, et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 2011; 17:179-188.
11. Han MS, Jung DY, Morel C, et al. JNK expression by macrophages promotes obesity-induced insulin resistance and inflammation. Science 2013; 339: 218-222.
12. Kanda H, Tateya S, Tamori Y, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006; 116:1494-1505.
13. Balistreri CR, Caruso C, Candore G. The role of adipose tissue and adipokines in obesity-related inflammatory diseases. Mediators Inflamm 2010; 2010:802078.
14. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 2006; 444:875-880.
15. Levi M, van der Poll T, Schultz M. Infection and inflammation as risk factors for thrombosis and atherosclerosis. Semin Thromb Hemost 2012; 38:506-514.
16. Levi M, van der Poll T, ten Cate H. Tissue factor in infection and severe inflammation. Semin Thromb Hemost 2006; 32:33-39.
17. Pan J, Xia L, McEver RP. Comparison of promoters for the murine and human P-selectin genes suggests species-specific and conserved mechanisms for transcriptional regulation in endothelial cells. J Biol Chem 1998; 273:10058-10067.
18. Freedman JE, LarsonMG, Tanriverdi K, et al. Relation of platelet and leukocyte inflammatory transcripts to body mass index in the Framingham Heart Study. Circulation 2010; 122:119-129.
19. Semple JW, Italiano JE Jr, Freedman J. Platelets and the immune continuum. Nat Rev Immunol 2011; 11:264-274.
20. Tichelaar YI, Kluin-Nelemans HJ, Meijer K. Infections and inflammatory diseases as risk factors for venous thrombosis. A systematic review. Thromb Haemost 2012; 107:827-837.
21. Shimomura I, Funahashi T, Takahashi M, et al. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 1996; 2:800-803.
22. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011; 11:85-97.
23. Alessi MC, Nicaud V, Scroyen I, et al. Association of vitronectin and plasminogen activator inhibitor-1 levels with the risk of metabolic syndrome and type 2 diabetes mellitus. Results from the D.E.S.I. R. prospective cohort. Thromb Haemost 2011; 106:416-422.
24. Belalcazar LM, Ballantyne CM, Lang W, et al. Metabolic factors, adipose tissue, and plasminogen activator inhibitor-1 levels in type 2 diabetes: findings from the look AHEAD study. Arterioscler Thromb Vasc Biol 2011; 31:1689-1695.
25. Singh A, Foster GD, Gunawardana J, et al. Elevated circulating tissue factor procoagulant activity, factor VII, and plasminogen activator inhibitor-1 in childhood obesity: evidence of a procoagulant state. Br J Haematol 2012; 158:523-527.
26. Samad F, Yamamoto K, Loskutoff DJ. Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide. J Clin Invest 1996; 97:37-46.
27. Lijnen HR. Role of fibrinolysis in obesity and thrombosis. Thromb Res 2009; 123 (Suppl 4):S46-S49.
28. Samad F, Loskutoff DJ. Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice. Mol Med 1996; 2:568-582.
29. Nagai N, Van Hoef B, Lijnen HR. Plasminogen activator inhibitor-1 contributes to the deleterious effect of obesity on the outcome of thrombotic ischemic stroke in mice. J Thromb Haemost 2007; 5:1726-1731.
30. Leal Vde O, Mafra D. Adipokines in obesity. Clin Chim Acta 2013; 419:87-94.
31. Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372:425-432.
32. Wallace AM, McMahon AD, Packard CJ, et al. Plasma leptin and the risk of cardiovascular disease in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 2001; 104:3052-3056.
33. Wolk R, Berger P, Lennon RJ, et al. Plasma leptin and prognosis in patients with established coronary atherosclerosis. J Am Coll Cardiol 2004; 44:1819-1824.
34. Bodary PF, Westrick RJ, Wickenheiser KJ, et al. Effect of leptin on arterial thrombosis following vascular injury in mice. JAMA 2002; 287:1706-1709.
35. Dellas C, Schafer K, Rohm IK, et al. Leptin signalling and leptin-mediated activation of human platelets: importance of JAK2 and the phospholipases Cgamma2 and A2. Thromb Haemost 2007; 98:1063-1071.
36. Nakata M, Yada T, Soejima N, Maruyama I. Leptin promotes aggregation of human platelets via the long form of its receptor. Diabetes 1999; 48:426-429.
37. Konstantinides S, Schafer K, Koschnick S, Loskutoff DJ. Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin Invest 2001; 108:1533-1540.
38. Singh P, Hoffmann M, Wolk R, et al. Leptin induces C-reactive protein expression in vascular endothelial cells. Arterioscler Thromb Vasc Biol 2007; 27:e302-e307.
39. Payne GA, Borbouse L, Kumar S, et al. Epicardial perivascular adiposederived leptin exacerbates coronary endothelial dysfunction in metabolic syndrome via a protein kinase C-beta pathway. Arterioscler Thromb Vasc Biol 2010; 30:1711-1717.
40. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001; 409:307-312.
41. Verma S, Li SH, Wang CH, et al. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 2003; 108:736-740.
42. Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307:426-430.
43. Revollo JR, Korner A, Mills KF, et al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab 2007; 6:363-375.
44. Kim SR, Bae YH, Bae SK, et al. Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells. Biochim Biophys Acta 2008; 1783:886-895.
45. Dahl TB, Holm S, Aukrust P, Halvorsen B. Visfatin/NAMPT: a multifaceted molecule with diverse roles in physiology and pathophysiology. Annu Rev Nutr 2012; 32:229-243.
46. Halvorsen B, Dahl TB, Aukrust P. Visfatin/NAMPT: a hot spot in thrombosis? Thromb Res 2012; 130:289-290.
47. Dahl TB, Yndestad A, Skjelland M, et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 2007; 115:972-980.
48. Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999; 100:2473-2476.
49. Ouedraogo R, Gong Y, Berzins B, et al. Adiponectin deficiency increases leukocyte-endothelium interactions via upregulation of endothelial cell adhesion molecules in vivo. J Clin Invest 2007; 117:1718-1726.
50. Arita Y, Kihara S, Ouchi N, et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 2002; 105:2893-2898.
51. Kumada M, Kihara S, Ouchi N, et al. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 2004; 109:2046-2049.
52. Chen YJ, Zhang LQ, Wang GP, et al. Adiponectin inhibits tissue factor expression and enhances tissue factor pathway inhibitor expression in human endothelial cells. Thromb Haemost 2008; 100:291-300.
53. Okamoto Y, Ishii S, Croce K, et al. Adiponectin inhibits macrophage tissue factor, a key trigger of thrombosis in disrupted atherosclerotic plaques. Atherosclerosis 2013; 226:373-377.
54. Boucher J, Masri B, Daviaud D, et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology 2005; 146:1764-1771.
55. Castan-Laurell I, Dray C, Attane C, et al. Apelin, diabetes, and obesity. Endocrine 2011; 40:1-9.
56. Charo DN, Ho M, Fajardo G, et al. Endogenous regulation of cardiovascular function by apelin-APJ. Am J Physiol Heart Circ Physiol 2009; 297:H1904-H1913.
57. Chun HJ, Ali ZA, Kojima Y, et al. Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis. J Clin Invest 2008; 118:3343-3354.
58. McLean DL, Kim J, Kang Y, et al. Apelin/APJ signaling is a critical regulator of statin effects in vascular endothelial cells: brief report. Arterioscler Thromb Vasc Biol 2012; 32:2640-2643.
59. Siddiquee K, Hampton J, Khan S, et al. Apelin protects against angiotensin II-induced cardiovascular fibrosis and decreases plasminogen activator inhibitor type-1 production. J Hypertens 2011; 29:724-731.
60. Scimia MC, Hurtado C, Ray S, et al. APJ acts as a dual receptor in cardiac hypertrophy. Nature 2012; 488:394-398.
61. Almeida MI, Reis RM, Calin GA. MicroRNA history: discovery, recent applications, and next frontiers. Mutat Res 2011; 717:1-8.
62. Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010; 466: 835-840.
63. Quiat D, Olson EN. MicroRNAs in cardiovascular disease: from pathogenesis to prevention and treatment. J Clin Invest 2013; 123:11-18.
64. Zampetaki A, Kiechl S, Drozdov I, et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res 2010; 107:810-817.
65. Shantikumar S, Caporali A, Emanueli C. Role of microRNAs in diabetes and its cardiovascular complications. Cardiovasc Res 2012; 93:583-593.
66. Kornfeld JW, Baitzel C, Konner AC, et al. Obesity-induced overexpression of miR-802 impairs glucose metabolism through silencing of Hnf1b. Nature 2013; 494:111-115.
67. Rayner KJ, Esau CC, Hussain FN, et al. Inhibition of miR-33a/b in nonhuman primates raises plasma HDL and lowers VLDL triglycerides. Nature 2011; 478:404-407.
68. Marchand A, Proust C, Morange PE, et al. miR-421 and miR-30c inhibit SERPINE 1 gene expression in human endothelial cells. PLoS One 2012; 7:e44532.
69. Harris TA, Yamakuchi M, Ferlito M, et al. MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc Natl Acad Sci U S A 2008; 105:1516-1521.
70. Fleissner F, Jazbutyte V, Fiedler J, et al. Short communication: asymmetric dimethylarginine impairs angiogenic progenitor cell function in patients with coronary artery disease through a microRNA-21-dependent mechanism. Circ Res 2010; 107:138-143.
71. Bray PF, McKenzie SE, Edelstein LC, et al. The complex transcriptional landscape of the anucleate human platelet. BMC Genomics 2013; 14:1.
72. Landry P, Plante I, Ouellet DL, et al. Existence of a microRNA pathway in anucleate platelets. Nat Struct Mol Biol 2009; 16:961-966.
73. Nagalla S, Shaw C, Kong X, et al. Platelet microRNA-mRNA coexpression profiles correlate with platelet reactivity. Blood 2011; 117:5189-5197.
74. Willeit P, Zampetaki A, Dudek K, et al. Circulating microRNAs as novel biomarkers for platelet activation. Circ Res 2013; 112:595-600.
75. Kondkar AA, Bray MS, Leal SM, et al. VAMP8/endobrevin is overexpressed in hyperreactive human platelets: suggested role for platelet microRNA. J Thromb Haemost 2010; 8:369-378.
76. Wallace JL, Reaves AB, Tolley EA, et al. Comparison of initial warfarin response in obese patients versus nonobese patients. J Thromb Thrombolysis 2012. [Epub ahead of print]
77. Frederiksen SG, Hedenbro JL, Norgren L. Enoxaparin effect depends on body-weight and current doses may be inadequate in obese patients. Br J Surg 2003; 90:547-548.
78. Garcia DA, Baglin TP, Weitz JI, et al. Parenteral anticoagulants: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e24S-e43S.
79. Frantz B, O'Neill EA. The effect of sodium salicylate and aspirin on NF-kappa B. Science 1995; 270:2017-2019.
80. Nieuwdorp M, Stroes ES, Meijers JC, Buller H. Hypercoagulability in the metabolic syndrome. Curr Opin Pharmacol 2005; 5:155-159.
81. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195-2207.
82. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011; 11:98-107.
83. Charo IF, Taub R. Anti-inflammatory therapeutics for the treatment of atherosclerosis. Nat Rev Drug Discov 2011; 10:365-376.
84. Fjellstrom O, Deinum J, Sjogren T, et al. Characterization of a small molecule inhibitor of plasminogen activator inhibitor type 1 that accelerates the transition into the latent conformation. J Biol Chem 2013; 288:873-885.
85. Fortenberry YM. Plasminogen activator inhibitor-1 inhibitors: a patent review (2006 - present). Expert Opin Ther Pat 2013. [Epub ahead of print]
86. Norris AW, Sigmund CD. A second chance for a PPARgamma targeted therapy? Circ Res 2012; 110:8-11.
87. Bodary PF, Vargas FB, King SA, et al. Pioglitazone protects against thrombosis in a mouse model of obesity and insulin resistance. J Thromb Haemost 2005; 3:2149-2153.
88. Mattu HS, Randeva HS. Role of adipokines in cardiovascular disease. J Endocrinol 2013; 216:T17-T36.
89. Vatier C, Gautier JF, Vigouroux C. Therapeutic use of recombinant methionyl human leptin. Biochimie 2012; 94:2116-2125.
90. Coppari R, Bjorbaek C. Leptin revisited: its mechanism of action and potential for treating diabetes. Nat Rev Drug Discov 2012; 11:692-708.
91. Barnes G, Japp AG, Newby DE. Translational promise of the apelin:APJ system. Heart 2010; 96:1011-1016.
92. Jia ZQ, Hou L, Leger A, et al. Cardiovascular effects of a PEGylated apelin. Peptides 2012; 38:181-188.
93. Wong WT, Tian XY, Xu A, et al. Adiponectin is required for PPARgammamediated improvement of endothelial function in diabetic mice. Cell Metab 2011; 14:104-115.
94. Eyries M, Siegfried G, Ciumas M, et al. Hypoxia-induced apelin expression regulates endothelial cell proliferation and regenerative angiogenesis. Circ Res 2008; 103:432-440.
95. Kidoya H, Naito H, Takakura N. Apelin induces enlarged and nonleaky blood vessels for functional recovery from ischemia. Blood 2010; 115:3166-3174.
96. Ishida M, Selaru FM. miRNA-based therapeutic strategies. Curr Anesthesiol Rep 2013; 1:63-70.
97. Lima WF, Prakash TP, Murray HM, et al. Single-stranded siRNAs activate RNAi in animals. Cell 2012; 150:883-894.